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More than 90% of all cancer-related deaths are the result of tumor metastases 1 . The physical process of tumor cell dissemination and metastatic colonization of distant secondary sites has been well described 2 . Whole-genome sequencing studies have elucidated the evolutionary phylogeny of metastatic dissemination 3, 4 , and gene expression studies have revealed many of the genes that mediate the progressive steps of metastasis and drive organ-specific colonization [5] [6] [7] . These studies suggest that adaptation of metastatic tumor cells to the microenvironment of their destination organ is accompanied by a shift in cell state attained through widespread changes in the transcriptional output of metastatic cell genomes. Whether the shift is driven by genetic factors, epigenetic factors, or a combination of both of these mechanisms is not yet clear.
During normal development, gene expression changes that accompany cell state transitions are driven by altered activity of gene enhancer elements [8] [9] [10] . Enhancers govern cell-type-specific expression programs and are defined by signature chromatin features, including the histone modifications H3K4me1 and H3K27ac and hypersensitivity to DNase 11 . Enhancers appear to be important in tumorigenesis as well. Previous studies have demonstrated that malignant transformation is accompanied by locus-specific gains and losses in enhancer activity across the epigenome; these are termed variant enhancer loci (VELs) 12, 13 . Others have shown that in many types of cancers, clusters of active enhancers called super-enhancers (SEs) mediate dysregulated expression of oncogenes 14, 15 . Collectively these studies suggest that aberrant enhancer activity is a key driver of tumor formation and maintenance.
Altered transcriptional programs play a role in metastatic tumor progression. These transcriptional programs have been associated with metastatic colonization of specific secondary organs [5] [6] [7] 16 . Recently, epigenetic changes have been associated with transcriptional changes during metastasis 17 . However, the contribution of gene enhancers to metastatic transcription is not well understood. On the basis of the knowledge that enhancers drive cell state transitions during normal development and tumorigenesis, we hypothesized that enhancers play a similar role in the transition of cancer cells from one developmentally distinct tissue to another during metastatic progression.
Osteosarcoma is the most common primary malignancy of bone, with peak incidence in children and adolescents. Clinical outcomes for patients have not improved over the past 30 years, and there are currently no approved targeted antimetastatic therapies for osteosarcoma in wide clinical use 18 . More than 75% of osteosarcoma metastases occur in the lung, and these are the cause of the overwhelming majority of osteosarcoma-related deaths 19 . In this study, we leverage the knowledge that gene enhancer activity is a cornerstone of cellular phenotypes and cell-type-specific gene expression 9, 20 to gain new insight into the regulatory mechanisms that allow metastatic osteosarcoma cells to overcome the barriers to colonization encountered as these cells engage the lung microenvironment. Our study establishes that enhancer elements endow tumor cells with the capacity to metastasize and that targeted inhibition of genes associated with high enhancer activity in metastatic cells, or genetic deletion of metastaticspecific enhancers themselves, can block metastasis.
RESULTS
The metastatic phenotype of human osteosarcoma is associated with variant enhancer loci We mapped the locations of putative enhancer elements across the genome through chromatin immunoprecipitation and sequencing (ChIP-seq) analysis of the canonical enhancer histone marks H3K4me1 and H3K27ac in matched primary tumors and lung metastases from five subjects with osteosarcoma. We also performed ChIP-seq for H3K4me1 and H3K27ac and DNase-seq in a panel of five well-characterized 21 metastatic and nonmetastatic (metastatic/ nonmetastatic) human osteosarcoma cell line pairs representing three distinct mechanisms of metastatic derivation, including in vivo selection (MG63.3/MG63, LM7/SaOS-2, M112/Hu09), treatment with a mutagenic compound (MNNG/HOS), and introduction of an oncogenic driver (143B/HOS) (Fig. 1a) . We used H3K4me1 for our initial comparisons based on the previous finding that this histone mark broadly correlates with both poised and active enhancers 22, 23 .
We found thousands of regions where H3K4me1 signals showed at least a threefold difference in enrichment between conditions (Fig. 1b,c) . The metastasis-associated gains and losses of the H3K4me1 signal were similar to those of the VELs that we had previously identified in the setting of primary tumor development through comparisons of primary colon tumors and healthy colon tissue 12, 13 . We herein term the regions that show differential enrichment of H3K4me1 between metastatic samples and nonmetastatic controls Met-VELs for distinction. Enhancers, defined by differential enrichment of H3K4me1, generally showed concordant changes in H3K27ac ChIP-seq and DNase-seq signals ( Fig. 1d and Supplementary Fig. 1 ), indicating robust commissioning and decommissioning of active enhancer elements at these loci. We found that, on average across all samples, 9.3% of all enhancers in a given metastatic cell line or tumor were gained relative to controls, whereas 16 .4% of enhancers present in nonmetastatic cell lines or primary tumors were lost (Fig. 1e) .
We next assessed the degree of Met-VEL heterogeneity across the cohort (Fig. 1f) . Met-VELs were more concordant between two metastatic cell lines (MNNG and 143B) derived from a single parental cell line (HOS) than between those derived from distinct parental cell populations (40.8% versus 0.2-9.3%, P < 0.001; χ 2 test with Monte Carlo correction), suggesting that the specific enhancer elements that undergo activation and silencing are nonrandom and may be driven in part by the genetic and/or epigenetic makeup of the parental cell line. Met-VELs were heterogeneous among the remaining samples, with 23-69.1% overlapping with at least one other sample and 4.2-18.4% overlapping with two or more samples. No Met-VELs were shared among all cell lines or tissue samples. The heterogeneity observed could be a result of different selective pressures between the experimental approaches used to derive the metastatic cell lines and also heterogeneity in the selective process of metastasis in subjects. Additionally, the genetic heterogeneity among primary osteosarcoma tumors may contribute to the epigenetic heterogeneity we observed in cell lines and tumors.
An initial survey of Met-VEL distribution revealed dense clusters at distinct regions across the epigenome that were often in the vicinity of individual genes, similar to the pattern seen with SEs ( Supplementary  Fig. 2a ). This finding led us to hypothesize that enhancer activity in these regions was nonrandomly acquired owing to selective pressures incurred during metastatic progression. We systematically tested this hypothesis and found numerous loci with Met-VEL counts significantly greater than expected by chance in all samples (clusters in exemplar pairs are displayed in Fig. 1g and Supplementary Fig. 2b) . Several of the genes associated with Met-VEL clusters in both primary human samples and in cell lines have been previously implicated in tumor biology and/or progression. Angiopoietin 1 (ANGPT1) is a TIE2 receptor tyrosine kinase agonist that plays a crucial role in angiogenesis and is currently being studied as a therapeutic target in multiple tumor types 24 . Growth hormone receptor (GHR) 25, 26 , phosphodiesterase 10A (PDE10A) 27 , and tissue factor (F3) have all been previously implicated in tumor biology and/or progression. F3 is a well-described activator of normal blood coagulation. F3 also plays an endogenous role within tumor cells to promote tumor growth and metastasis in multiple cancers, but the mechanism underlying its activation is not fully defined 28 . All metastatic/nonmetastatic cell lines and primary and metastatic tumor pairs studied showed evidence of nonrandom acquisition and loss of enhancer clusters ( Supplementary  Fig. 2c ). On average across the cohort, 22% of all Met-VELs were found to reside in Met-VEL clusters (Supplementary Fig. 2d ).
Met-VELs dynamically modulate gene expression as tumor cells engage the lung microenvironment
We used an ex vivo mouse model of osteosarcoma lung metastasis 29 to investigate the role of Met-VELs in modulating gene expression during metastasis. In this model, we seeded GFP-expressing tumor cells to the lungs of mice through intravenous injection. We then removed the lungs and grew lung sections in ex vivo culture. This approach allowed us to track metastatic outgrowth of GFP-labeled tumor cells in real time and to assess dynamic changes in gene expression (Fig. 2a) . We performed RNA-seq at both early (24 h) and late (day 14) time points following injection in three metastatic/nonmetastatic cell line pairs. We determined the association between Met-VELs and their predicted target genes using PreSTIGE 30 and validated that >94.5% of predicted Met-VEL gene targets were located within the same topologically associating domains as their corresponding enhancer. In all cases, genes associated with gained Met-VELs and Met-VEL clusters were generally expressed at higher levels in metastatic cells within the lung microenvironment than in the corresponding nonmetastatic parental cell lines, whereas genes associated with lost Met-VELs and Met-VEL clusters were expressed at lower levels ( Fig. 2b and Supplementary Fig. 3a,b) . We compared the expression of gene sets associated with Met-VELs across conditions to investigate whether these represent a transcriptional program that is specifically modulated in metastasis. The degree Fold change (log 2 (metastatic/nonmetastatic)) © 2018 Nature America, Inc., part of Springer Nature. All rights reserved.
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of differential expression of Met-VEL-associated genes in the parental versus metastatic cells was greater in ex vivo lung culture than in standard in vitro culture conditions ( Supplementary Fig. 4a,b) , indicating that modulation of these transcriptional programs represents a cellular response to external cues from the lung microenvironment. Met-VEL-associated gene sets showed little overlap (<27%) with the most differentially expressed genes in each metastatic/nonmetastatic cell line pair, indicating that the Met-VEL-associated genes represent a set distinct from those likely to be identified using expression data alone ( Supplementary Fig. 4c,d) .
Subsets of genes associated with gained Met-VELs became highly expressed within 24 h of the arrival of metastatic cells in lung; other gene subsets were only activated later during metastatic outgrowth, and a third subset was constitutively upregulated (Fig. 2c and  Supplementary Fig. 3c ). We assessed these gene sets for functional enrichment and found that the phasic waves of gene expression coordinated by Met-VELs during lung colonization were associated with distinct cellular functions ( Fig. 2d and Supplementary Fig. 3e) . We verified that genes associated with gained Met-VELs and upregulated in ex vivo lung culture frequently had elevated expression in lung metastases from individuals with osteosarcoma relative to primary tumors (Fig. 2e) . We also found that genes associated with gained MetVELs in patient metastases showed similar functional enrichment to the cell line gene sets (Supplementary Fig. 5 ). These results verify that the genes identified using the cell line models and the ex vivo approach are representative of those that are dysregulated in human tumors.
We next performed motif enrichment analysis and identified a number of commonly expressed transcription factors (TFs) with enriched binding-site motifs in gained and lost Met-VELs across all three pairs analyzed. The most highly enriched motifs include those for many members of the activator protein 1 (AP-1) complex (JUN, JUNB, JUND, FOS, and FOSL1; Fig. 2f and Supplementary  Fig. 3d ), which has previously been shown to play a key role in osteosarcoma metastasis 31 . Intriguingly, the binding-site motifs for AP-1 complex TFs were enriched in both gained and lost Met-VELs. This finding suggests that Met-VELs likely alter the transcriptional programs mediated by AP-1 during osteosarcoma metastasis. We verified through ChIP-seq that FOS and FOSL1 are bound at gained Met-VELs (Fig. 2g) .
Met-VEL-associated gene expression is required for metastatic colonization We reasoned that BRD4 inhibition may interrupt Met-VEL-associated gene expression and metastasis on the basis of the finding that gained Met-VELs have high levels of the activating histone mark H3K27ac and the knowledge that the bromodomain and extraterminal (BET)-family protein BRD4 is critical for transcriptional activation through H3K27ac-marked enhancers. To test this hypothesis, we used the BRD4 inhibitor JQ1, which displaces BRD4 from H3K27ac-marked enhancers 15, 32 . JQ1 has been shown to inhibit primary tumor formation in osteosarcoma through its effects on both tumor cells and bone cells within the tumor microenvironment 33 . We found that JQ1 had potent antiproliferative effects on metastatic tumor cells growing in the lung microenvironment without affecting the surrounding healthy lung tissue ( Supplementary Fig. 6a-c) . These antiproliferative effects were associated with selective suppression of target genes of gained Met-VELs that are normally upregulated in metastatic cells in response to cues from the lung microenvironment ( Supplementary Fig. 6d,e) . Intriguingly, JQ1 more potently suppressed genes associated with gained Met-VELs than SE-associated genes ( Supplementary Fig. 6f ) that have previously been linked to JQ1's antitumor properties in other tumor models 15, 34, 35 .
The results of the JQ1 studies suggest that activation of gained Met-VEL-associated genes is necessary for metastatic outgrowth. To further test this hypothesis, we conducted a functional in vivo RNAi screen. We constructed a custom shRNA library targeting 33 genes. This gene list included 20 genes associated with gained Met-VELs or Met-VEL clusters, 11 TFs with binding-site motifs enriched in Met-VELs, and 2 genes of interest from other ongoing studies. We cloned the shRNA library into a tetracycline-inducible lentiviral construct (LT3REPIR; Fig. 3a ) modified from a similar construct previously published 36 . Using a Discosoma sp. red fluorescent protein (dsRed) fluorescent reporter of shRNA induction, we show that this construct was robustly induced upon exposure to doxycycline and not leaky in the absence of doxycycline (Supplementary Fig. 7 ). We conducted parallel screens in vivo and in vitro to allow us to distinguish genes that specifically inhibit metastatic outgrowth in the in vivo microenvironment, termed metastasis dependency genes, from genes whose inhibition reduces cellular growth independent of context ( Fig. 3b) .
In the in vivo screen, transduced cells were delivered via injection in tail veins of mice pretreated with doxycycline. Mice were maintained on doxycycline throughout the 21-d course of the experiment. In the parallel in vitro screen, transduced cells were treated in culture with doxycycline for 21 d. At the conclusion of the experiment, induced cells actively expressing shRNA (GFP + dsRed + ) were sorted from mouse lung or in vitro culture through fluorescence-activated cell sorting (FACS). DNA was isolated from these cells along with noninduced cells from the initial population (input), and the shRNAs were amplified, sequenced, and aligned to the reference shRNA sequences in the library to determine normalized representation for each shRNA.
We defined metastasis dependency genes as those whose knockdown inhibited in vivo metastasis at least 2.5-fold more than in vitro growth. First, shRNA representations in metastatic tumor cells were compared to input representations to identify shRNAs depleted from the population of cells during metastatic outgrowth in lung (Fig. 3c) . Genes were defined as initial hits when they were a target of at least two unique shRNAs (the pool contained three or four shRNAs per gene) that inhibited metastatic outgrowth to a greater degree than all negative controls. Because we used a second filter for these hits in this screen and planned further functional validation experiments, we intentionally chose a relatively inclusive threshold for initial-hit calling. We found that 13 of 33 genes (39%) included in our screen met this criterion. To determine whether the depletion of cells expressing these shRNAs was specific to metastasis, we compared the relative representation of hits in the population of cells induced in vivo to the controls induced in vitro (Fig. 3d) . Genes targeted by shRNAs that were significantly more depleted in vivo than in vitro were considered metastasis dependency genes; 6 of the 13 initial hits met this criterion (Supplementary Table 1) . Metastasis dependency genes included four genes (F3, FBXO42, FLNA, and FOXO3) associated with gained Met-VEL clusters as well as two genes (FOS and FOSL1) encoding AP-1 complex TFs that had bindingsite motifs enriched in Met-VELs and that were shown to bind at these enhancers. These results indicate metastatic colonization of the lung by osteosarcoma cells is dependent on expression of a subset of individual genes associated with gained Met-VEL clusters as well as AP-1 complex TFs that are likely to regulate Met-VEL transcriptional programs.
Among the Met-VEL-associated genes, F3 emerged as a top candidate driver of metastasis in osteosarcoma. In the MG63.3 cell line, F3 was associated with a gained Met-VEL cluster containing the secondhighest gained Met-VEL count among the entire data set (Fig. 1g) , suggesting that this locus was under particularly strong positive selection during metastatic derivation. Gained Met-VELs in the F3 cluster also showed higher levels of H3K27ac and increased DNase sensitivity in MG63.3 cells as compared to the parental MG63 cell line, and chromatin conformation capture studies confirmed that these enhancers physically contact the transcription start site of F3 (Supplementary Fig. 8a ). F3 was more highly expressed in MG63.3 cells during metastatic outgrowth than in the parental MG63 cells (Supplementary Fig. 8b ). In addition, two other metastatic cell lines, MNNG and 143B, © 2018 Nature America, Inc., part of Springer Nature. All rights reserved.
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showed active enhancer signals at the F3 locus, similar to MG63.3 ( Supplementary Fig. 8d ), and expressed F3 at higher levels during metastatic outgrowth than their respective parental cell line ( Supplementary Fig. 8b ). To verify that elevated F3 transcript levels were recapitulated at the protein level and also were not an artifact of ex vivo culture, we performed immunofluorescence analysis of lung metastases from a fully in vivo model of metastasis and confirmed that metastatic osteosarcoma cells expressed higher levels of F3 protein than nonmetastatic cells (Fig. 4a,b) . Quantification of F3 expression levels directly in human osteosarcoma samples showed that F3 expression was elevated in lung metastases relative to primary tumors ( Supplementary Fig. 8c ). Using a tissue microarray, we confirmed that F3 protein was highly expressed in lung metastases from human osteosarcoma patients. F3 was expressed in >50% of tumor cells in 18 of 18 lung metastases, and F3 had strongly positive staining in 17 of 18 samples (Fig. 4c,d and Supplementary Fig. 9 ). We analyzed the enhancer epigenomes of ten pairs of matched primary and metastatic tumors to determine whether F3 upregulation in osteosarcoma lung metastases was a result of enhancer dysregulation. Although we did not observe de novo creation of a sufficient number of gained Met-VELs at the F3 locus for it to meet the criteria to be called a gained cluster, this locus has an enhancer cluster that in 9 out of 10 metastatic samples was called as a SE and ranked among the sites most enriched for H3K27ac (Supplementary Fig. 10a ).
Comparison of the SE landscapes across all samples showed that the F3 SE was among the top 1.3% of SEs enriched in lung metastases relative to primary tumors (P < 0.05, t-test). This was true when metastatic tumors were compared to primary tumors alone and when metastatic/nonmetastatic cell lines were included in the analysis (Supplementary Fig. 10b) .
We further investigated the enhancer profiles of these ten paired samples and verified that common target genes of Met-VELs in cell lines often overlapped with common Met-VEL targets in samples of primary tumors (Supplementary Table 2) .
We next tested the functional contribution of F3 expression to the metastatic phenotype. We cloned two shRNAs targeting F3, which were not included in the RNAi assay, into the tetracycline-inducible LT3REPIR construct. Relative to that in noninduced control cells, F3 expression was reduced by 44-63% 40 h after induction of each shRNA (Supplementary Fig. 11 ). F3 knockdown with these shRNAs did not affect the in vitro growth rate of metastatic MG63.3 or MNNG cells (Supplementary Fig. 12a ) but significantly reduced metastatic outgrowth of these cells in ex vivo lung culture ( Supplementary  Fig. 12b,c) , supporting the metastasis-specific role for F3 in this setting. F3 knockdown also significantly reduced metastatic outgrowth of osteosarcoma cells in vivo ( Supplementary Fig. 12d ,e) and substantially prolonged survival of mice injected with metastatic osteosarcoma cells (Fig. 4e) . To further test whether F3 knockdown reduced in vivo growth of metastatic cells generally or specifically in the context of metastatic outgrowth of cells in lung, we performed a spontaneous metastasis experiment using an orthotopic injection model. We found that F3 knockdown did not reduce primary tumor development or growth (Fig. 4f) but significantly inhibited metastasis, reducing the average metastatic burden by 3.6-fold (Fig. 4g,h ). Although extensive GFP + metastatic Fig. 11 ; n = 5 mice per condition) via tail vein. The P value was calculated using the Gehan-Breslow-Wilcoxon test. lesions were observed in control mice, lungs of mice in the F3-knockdown group were virtually devoid of metastatic lesions, with only rare single GFP + cells observable in most cases (Supplementary Fig. 13 ). F3 is known to both induce blood coagulation through mediating the generation of the active form of factor X (FXa) and promote cell survival and proliferation upon binding to activated factor VII via intracellular signaling mechanisms 28 . To determine the relative contribution of each of these functions to the prometastatic role of F3, we used monoclonal antibodies generated to inhibit each function independently 37 . As expected, we found that MG63.3 cells produced more FXa in an in vitro assay than MG63 cells did (Fig. 4i) . We confirmed that anticoagulant monoclonal antibody 5G9 robustly inhibited this activity, whereas monoclonal antibody 10H10, designed to prevent intracellular signaling, did not. We next tested the antimetastatic effects of these antibodies in vivo. We co-injected MG63.3 cells with each antibody or with IgG control into tail veins of mice and found that both inhibited metastasis, with monoclonal antibody 5G9 showing a more pronounced effect (Fig. 4j,k) . These results indicate that both the intracellular signaling and procoagulant functions of F3 contribute to metastatic progression, but the procoagulant activity of F3 is especially critical for metastatic success. Collectively, these findings suggest that Met-VELs regulate expression of genes with critical functions during metastatic progression, such as F3.
To directly test the role of Met-VELs in mediating the metastatic phenotype, we employed transcription activator-like effector nuclease (TALEN) genome editing to excise one of the gained Met-VELs predicted to regulate F3 in metastatic cells. We targeted a Met-VEL located in a particularly robust DNase hypersensitivity site site containing high levels of both H3K4me1 and H3K27ac (Fig. 5a) . This site also showed high ChIP-seq enrichment for both FOS and FOSL1 AP-1 complex members. We generated a cell clone with homozygous deletion of this Met-VEL, which was verified using Sanger sequencing (Fig. 5a) . Edited cells and unedited control cells were then seeded to mouse lungs via intravenous tail vein injection, and growth of the cells was monitored in the lungs using the ex vivo metastasis assay. Quantification of F3 levels at 24 h following injection showed that F3 expression in the edited cells was reduced by 34% relative to unedited control cells (Fig. 5b,c) . tumor cells, whereas extensive GFP + metastatic lesions were observed in lungs seeded with the unedited cells (Fig. 5d) . Quantification showed that deletion of this gained Met-VEL decreased metastatic burden by 78% relative to unedited cells (Fig. 5e) .
DISCUSSION
Although many of the genes responsible for metastatic progression have been identified across tumor types, the underlying mechanisms regulating expression of these genes are not well defined. Our studies demonstrate that altered enhancer activity is a fundamental mechanism through which tumor cells regulate gene expression during the dynamic process of metastasis and thereby acquire metastatic traits. Through epigenomic profiling experiments, we identified enhancers that distinguished human osteosarcoma lung metastases from matched primary tumors and verified that these differences were also present in near-isogenic metastatic/nonmetastatic paired human osteosarcoma cell lines. Subsets of these enhancer changes occurred in nonrandom clusters, indicating that they were positively selected during the process of metastatic derivation. These results demonstrate that the metastatic phenotype is accompanied by a shift in the enhancer epigenome, similar to the enhancer shifts that occur as cells transition through successive stages of embryonic development [8] [9] [10] or during conversion of a healthy cell to a malignant state 12, 14, 15 . Our findings suggest that the evolutionary selective forces encountered by tumor cells during metastasis act to shape the enhancer landscape of metastatically successful cancer cell populations. The result of this selection is a population of cells possessing all of the traits necessary to overcome the barriers to metastatic colonization in distant tissues. Indeed, we show that many genes previously associated with metastasis become dysregulated through alterations in enhancer activity. We provide multiple lines of evidence that acquired enhancer changes in metastatic osteosarcoma cells are functional and relevant to the osteosarcoma metastatic phenotype in experimental models and human tissues. First, we show that Met-VEL-associated genes are dynamically regulated as metastatic cells engage the lung microenvironment and proliferate. Second, we demonstrate that metastatic cell outgrowth in the lung can be mitigated through BET inhibition, and that this effect is associated with selective suppression of genes that are normally activated by Met-VELs in the lung. Third, through in vivo functional RNAi-based assays, we demonstrate that the metastatic capacity of the osteosarcoma cells can be diminished through targeted inhibition of individual Met-VEL-associated genes and associated AP-1 family TFs that likely regulate Met-VEL transcriptional programs. Using a fully in vivo model of spontaneous metastasis, we further verify that one such Met-VEL-associated gene, F3, is a clinically relevant, bona fide metastasis dependency gene that is essential for metastatic colonization but does not have an apparent role in primary tumor growth. Interrupting the signaling and procoagulant functions of F3 was sufficient to inhibit metastasis, shedding light on the biological role of this gene in the metastatic progression of osteosarcoma. Our genomic Met-VEL-deletion experiments demonstrate that the loss of function of a single gained enhancer at the F3 locus was sufficient to impair metastatic colonization and subsequent outgrowth in mice, indicating that enhancer activation contributed to acquisition of the metastatic phenotype in these cells.
Our current model for lung colonization by metastatic osteosarcoma cells involves a requirement for upregulation of F3 expression via the aberrant activation of its enhancers. It is not yet clear whether neutralizing F3 after colonization would lead to regression of overt metastases. The current standard of care for osteosarcoma involves multiple cycles of neoadjuvant combination chemotherapy before surgical removal of the primary tumor 18 . As such, there is a period of several months between the time of diagnosis and primary tumor control. This treatment period is critical, as there is continued potential for cells to leave the primary tumor and seed the lung. We believe that the most clearly indicated therapeutic setting for F3 inhibition would be during this period of neoadjuvant therapy. The findings described here may present a rationale for testing F3 inhibition in such a setting. Further studies are required to determine whether there may be clinical benefit from continued F3 inhibition after primary tumor control is achieved.
Collectively, our findings indicate that altered enhancer activity is a driver of gene expression that is critical for tumor cells, allowing them to overcome the barriers of distant tissue colonization during metastasis. It is well established that primary tumor formation is driven by a combination of genetic and epigenetic events 38 . With respect to metastasis, studies have shown that primary and matched metastatic tumors are broadly similar at the genetic level with no recurrent mutations identified in metastases that were not present in the primary tumor 3, 4, [39] [40] [41] [42] [43] [44] . These studies suggest that primary tumors are likely already genetically equipped with the ability to metastasize. Further, this implies that epigenetic processes may mediate the shift in cell state that accompanies metastatic progression, as proposed by others 17, [45] [46] [47] [48] . In accordance with this epigenetic hypothesis, we show that osteosarcoma metastasis is accompanied by a shift in epigenetic state at enhancer elements. Although our findings are not mutually exclusive with genetic theories of metastatic progression, we find that positive selection of enhancer activity is a fundamental component of the metastatic phenotype.
Our findings add to the growing body of evidence implicating epigenomic processes in metastasis. McDonald et al. 17 recently showed that pancreatic cancer metastasis is associated with widespread changes to heterochromatin, defined by H3K9 and H4K20 methylation. Denny et al. 49 found that differences in chromatin accessibility correlated with metastatic progression in NFIB-driven small cell lung cancer. Most recently, Roe et al. 50 showed that aberrant enhancer activity mediated by FOXA1 promotes metastasis in pancreatic cancer. Collectively, these studies demonstrate that chromatin changes drive the metastatic phenotype across various cancers. Our findings are well aligned with these studies but further implicate enhancer dysregulation as the basis of metastatic trait acquisition and demonstrate that such dysregulation presents an opportunity for the development of targeted antimetastatic therapies, as illustrated at the F3 locus.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
ONLINE METHODS
Cell culture. Human osteosarcoma cell lines were obtained and cultured as previously described 21 . MG63.3 cells were derived from MG63.2 through metastatic selection in mice as previously described 51 .
The metastatic properties of these clonally related parental and metastatic cell lines have been thoroughly characterized in multiple murine models of metastasis 21 . A sample size of five cell line pairs was chosen on the basis of similar studies completed by our lab in the past in order to capture the spectrum of methods of metastatic derivation and to sufficiently power comparative analyses of results.
The purity and authenticity of all lines used in these studies were independently confirmed through short tandem repeat (STR) profiling performed by the International Cell Line Authentication Committee. Mycoplasma testing was routinely performed with Mycoalert Mycoplasma detection kit (Lonza).
Mouse studies. All mice were housed and handled in accordance with protocols approved by the Case Western Reserve University Institutional Animal Care and Use Committee (IACUC) or the National Cancer Institute IACUC, depending on the location of the performed studies. The number of mice included in each of the described studies was based on extensive past experience in the development and use of murine models of metastases by our group. Each study was designed to minimize unnecessary mouse use, optimize statistical power, and account for known variance in each model system. Within each experiment, mice of the same strain, sex, and age were used for all conditions. At the initiation of each experiment, mice were randomly assigned to cages, and all mice in a given cage received equivalent treatment (for example, doxycycline). Researchers were not blinded to the group assignments of mice, as no subjective measurements were used.
Human subjects. Osteosarcoma primary tumors and lung metastatic tumors were obtained from the Laboratory of Experimental Oncology, Rizzoli Institute, Bologna, Italy with approval from Rizzoli Institute Ethics Committee and with informed written consent. A waiver was granted for informed consent from subjects deceased at the time of data collection, adhering to the European Union General Data Protection Regulation. Estimated tumor cellularity for the samples ranged from 50-90%.
Ex vivo lung metastasis assay. Procedure for RNA isolation. GFP + tumor cells (5 × 10 5 ) were injected into the tail vein of 8-to 10-week-old female SCID/Beige mice (Charles River). Within 15 min of tumor cell injection, mice were euthanized via CO 2 inhalation, and lungs were insufflated with a mixed agarose media solution. Lung sections for ex vivo culture were generated as previously described 29 and were incubated at 37 °C in humidified conditions of 5% CO 2 . Culture media was changed, and lung sections were flipped every 2 d. Tumor cell RNA was harvested at 24 h and 14 d after injection from one mouse for each condition. Lung sections were chopped into fine pieces and incubated in 3 ml Hank's balanced salt solution (HBSS) with 1 mg/ml collagenase at 37 °C for 30 min. EDTA was added to attain a final concentration of 10 mM, and the solution was placed on ice to stop digestion. Digested material was homogenized via passing it through an 18-gauge needle three to five times using a 10-ml syringe. Homogenate was passed through a 70-µm cell strainer (Corning Life Sciences) and centrifuged at 500g for 5 min at 4 °C. Supernatant was aspirated, and cells were resuspended in 5 ml ammonium-chloride-potassium (ACK) lysing buffer for 3 min at RT to lyse red blood cells. Lysis was stopped through addition of 10 ml HBSS, and cells were centrifuged at 500g for 5 min at 4 °C. Supernatant was aspirated, and cells were resuspended in 2-3 ml 0.5 mM EDTA-PBS and placed on ice. Immediately before sorting, cells were passed through a 40-µm cell strainer (Corning Life Sciences).
Cells were using FACS to isolate GFP + tumor cells and then were immediately centrifuged at 500g for 5 min at 4 °C. Supernatant was aspirated, cells were lysed in 1 ml TRIzol reagent (Life Technologies), and RNA was extracted with 200 µl chloroform. The organic phase was isolated, and 700 µl of ethanol was added. RNA was purified from this solution using the RNeasy Micro Kit (Qiagen).
Procedure for F3 knockdown studies. F3-knockdown cells were pretreated with 5 µg/ml doxycycline for 40 h in standard culture. Cells expressing shRNA targeting F3 were sorted using FACS to isolate dsRed + GFP + fraction. Noninduced control cells were sorted to isolate the GFP + fraction. 2 × 10 5 cells were injected into the tail vein of each mouse. For the F3 knockdown condition, 5 µg/ml doxycycline was added to agarose media solution used to insufflate lungs as well as culture media. The medium was changed, and fresh doxycycline was added every 2 d. A total of 8 lung sections were imaged for each condition (4 sections per mouse, 2 mice per condition).
Procedure for JQ1 studies. 5 × 10 5 tumor cells were injected into the tail vein of each mouse. For JQ1-treated cultures, medium was supplemented to a final concentration of 250 nM JQ1 by adding 10 mM DMSO stock solution. Vehicletreated culture medium was supplemented with DMSO volumes matching JQ1 treatment. The medium was changed, and fresh JQ1 or DMSO was added every 2 d. A total of 8 lung sections were imaged for each condition (4 sections per mouse, 2 mice per condition).
Assessment of metastatic burden. Lung sections were imaged by inverted fluorescent microscopy (Leica DM IRB) at a magnification of 2.5×. Two or three images per lung section were taken to capture the entire surface of each section. Image analysis was performed using ImageJ software to quantify the total GFP + area per lung section. The metastatic burden was calculated by normalizing the total GFP + area to the GFP + area for each section on day 0. The values reported represent the mean normalized tumor burden for all sections for each condition (8 sections per condition).
In vitro RNA isolation. To match the conditions used to isolate cells from ex vivo lung sections, cells growing in vitro were trypsinized, exposed to the same mechanical and enzymatic digestion conditions, and sorted through FACS as described above. 5 × 10 5 GFP + cells were collected, and RNA was isolated as described above.
ChIP-seq. ChIPs were performed using 5 × 10 6 to 10 × 10 6 cross-linked cells, and sequencing libraries were prepared as previously described 52 . The following antibodies were used for ChIP: rabbit anti-H3K4me1 (Abcam no. 8895), rabbit antiH3K27ac (Abcam no. 4729), rabbit anti-c-Fos (Santa Cruz no. sc-52), and rabbit anti-FOSL1/Fra-1 (Santa Cruz no. sc-605). ChIP-seq libraries were sequenced on the HiSeq 2000 or 2500 platform at the Case Western Reserve University Genomics Core Facility. Analysis was performed as previously described 8 .
Met-VEL analysis. H3K4me1 ChIP-seq peaks were filtered to remove all peaks overlapping ENCODE blacklisted regions for functional genomics analysis (https://sites.google.com/site/anshulkundaje/projects/blacklists/) as well as peaks ± 1 kb from transcription start sites of all annotated RefSeq genes to exclude promoters. Resulting peak lists of parental and metastatic cell line pairs were merged, and RPKM values within merged peaks were calculated. Gained and lost Met-VELs were called as peaks with RPKM values in metastatic cell lines that were increased or decreased threefold relative to parental cell lines, respectively. To determine the fraction of differentially active enhancers in different cell types (Supplementary Fig. 2 ), H3K4me1 ChIP-seq peaks for each pair of samples were filtered for ENCODE blacklisted regions and promoters, concatenated, and merged. Peak RPKMs were calculated for each sample in a pair and floored to 0.3. Differentially active enhancers were defined as those showing a threefold change in H3K4me1 signal in one sample relative to the other. The fractions of differentially active enhancers for the osteosarcoma tumors, and cell line panels were based on averages for each group.
Met-VEL clustering analysis. Global Met VEL distribution was assessed by calculating Met-VEL counts in 200-kb sliding windows across all chromosomes. Met-VEL islands were defined as regions bordered by 200-kb windows with Met-VEL counts of 0. 200-kb windows with maximum Met-VEL counts in each Met-VEL island were identified. To test for nonrandom Met-VEL distribution, the same analysis was performed on 1,000 Met-VEL-size-matched H3K4me1 peak lists randomly sampled from all H3K4me1 peaks in the cell line being analyzed to account for global enhancer distribution biases. Metastatic cell line H3K4me1 peaks were sampled to assess gained Met-VEL clustering. Parental cell line H3K4me1 peaks were sampled to assess lost Met-VEL clustering. The sampled lists were used to define expected distributions of random VEL acquisition in each cell line. Expected distributions were compared to observed distributions to test the null hypothesis of random Met-VEL acquisition.
A P value threshold of 0.05 was used to reject the null hypothesis in support of nonrandom acquisition of Met-VELs. 200-kb windows with Met-VEL counts exceeding these thresholds were called as Met-VEL clusters.
Super-enhancers. Metastatic cell line-and parental cell line-specific SEs were identified from their H3K27ac profiles using the ROSE software (https://github.com/BradnerLab/pipeline/). Analysis was performed as previously described 8 .
RNA-seq.
Gene expression profiles of cell lines grown in vitro were compared to expression profiles of the same cell lines at various time points during metastatic colonization using the ex vivo pulmonary metastasis assay. RNA quality was assessed by 2200 TapeStation Instrument (Agilent). PolyA + RNA was isolated using the Illumina TruSeq RNA Sample Preparation Kit according to the manufacturer's protocol. RNA-seq libraries were sequenced on the Illumina HiSeq 2000 or 2500 platform at the Case Western Reserve University Next Generation Sequencing Core Facility. Expression analysis was performed as previously described, aligning to the hg19 genome build 8 . FPKMs were quantile normalized across all samples.
Prediction of gene targets of enhancers.
Enhancer-gene assignments were made as previously described 30 . To identify Met-VEL gene targets in subject tissues that we did not have RNA-seq data for, we used the GREAT software package 53 to generate an initial list of candidate Met-VEL gene targets. We further filtered this list by only including genes within the same topologically associating domain as an enhancer with a H3K27ac peak at its promoter using a P value cutoff of P < 1 × 10 −5 . We then assessed overlaps in predicted Met-VEL gene targets between cell lines and subject tissues using the resulting gene lists. 54 to generate enrichment scores for all GO, Kyoto encyclopedia of genes and genomes (KEGG), and REACTOME gene sets according to the recommended settings for gProfiler (http://baderlab.org/ Software/EnrichmentMap/GProfilerTutorial/). Cytoscape (v3.2.1) and the Enrichment Map 55 plug-in were used to generate networks for enriched gene sets with a false discovery rate cutoff of <0.05.
Gene ontology analysis. Gained Met-VEL gene lists. Met-VEL gene lists were imported into gProfiler
Lost Met-VEL gene lists. For GO analysis, the genes associated with Met-VELs were analyzed using DAVID (http://david.abcc.ncifcrf.gov/home.jsp). A P value of 10 −3 was used as the threshold for significant enrichment of an ontologic category. Categories significantly enriched for genes associated with gained or lost Met-VELs in two or more pairs are reported, limiting overlapping lists to the three top-scoring categories in each cell line (i.e., the categories with the lowest P values).
DHS-seq. 6.4 × 10 6 -56 × 10 6 cells from each cell line were sequenced for DNase hypersensitivity as previously described 56 . A ribose 5-phosphate was added to linker 1B to increase ligation efficiency. After DNase concentrations were optimized for each line, a total of approximately 1 × 10 6 cells from optimally digested conditions were processed for sequencing. Libraries were sequenced on the HiSeq 2500 platform at the Case Western Reserve University Genomics Core Facility. Analysis was performed as previously described 8 .
Chromosome conformation capture sequencing. Chromosome conformation capture sequencing (4C-seq) sample preparation was performed as previously described 57 . NlaIII served as a primary restriction enzyme, DpnII as a secondary 4-bp cutter. The primer sequences used for 4C-seq analysis are as follows: forward, 5′-CTGTAAACTTGCCAAGCATG-3′; reverse, 5′-GGTCGCACAGGAGAAAGG-3′. Amplified sample libraries were pooled and spiked with 40% PhiX viral genome sequencing library to increase sample diversity. Multiplexed sequencing was performed on the MiSeq platform. Demultiplexing was performed using an in-house algorithm, and all reads were hard trimmed to 36 bp. Clipping of the primer sequences and data processing were performed using 4Cseqpipe Version 0.7 (http://compgenomics.weizmann. ac.il/tanay/?page_id=367). The viewpoint reads were aligned to a fragmented genome, as determined by the restriction site positions of the chosen primary and secondary restriction enzymes. A running linearly weighted mean, calculated in 2-to 50-kb sliding windows, was used for signal smoothing of each genomic bin (size 16 bp). Contact enrichment sites along the chromosomal axis were visually inspected.
Motif analysis.
To identify TF motifs enriched in Met-VEL peaks, enhancers were centered on DNase hypersensitivity sites and the SeqPos module of the Cistrome tool was used to scan a 1-kb window for enriched curated motifs 58 . Significantly enriched motifs in each cell line were then filtered using RNA-seq data, and only expressed TFs were used for downstream analysis. Expressed TFs with enriched motifs in 3 out of 3 metastatic/parental cell line pairs (MG63.3/ MG63; MNNG/HOS; 143B/HOS) are presented in the results.
In vivo RNAi high-throughput functional assay. Vector construction. The Tet-ON lentiviral construct was made via modifying the previously published optimized shRNAmir, miR-E, with a pRRL backbone 36 . Briefly, this construct contains an optimized 3rd-generation Tet-responsive element and reverse tetracycline transactivator to potentiate a positive feedback loop, enhancing expression of the construct upon induction and reducing construct leakiness. The version of the construct that we modified contained a constitutive Venus reporter and an induced dsRed reporter of expression (LT3REVIR). The construct was modified using standard cloning techniques to replace the Venus reporter with a puromycin-resistance element (renamed LT3REPIR) so that cells already constitutively expressing GFP could be selected for transduction.
shRNA library generation. shRNAs targeting 33 genes were selected from the transOMIC technologies shERWOOD-UltramiR shRNA library (3 or 4 shRNAs per gene). Cloning of shRNA into the backbone construct was performed on contract by transOMIC technologies. The shRNA sequences that were included are listed in Supplementary Table 3 , where scores indicate shERWOOD metric of predicted potency of each shRNA as assigned by previously described algorithm 59 . "#N/A" indicates that the shRNA failed to clone into the lentiviral backbone.
Lentiviral production. VSV-G-pseudotyped lentivirus was generated through standard laboratory techniques. Briefly, shRNA-LT3REPIR plasmids were co-transfected with packaging vectors psPAX2 and pCI-VSVG (Addgene) into 293FT cells using Cal-Phos Mammalian Transfection Kit (Clontech). Individual supernatants containing virus were harvested at 48 and 72 h posttransfection and filtered with a 0.45-µm PVDF membrane (Millipore).
Lentiviral transduction and selection. Transduction of MG63.3 was performed via 24-h exposure to lentivirus in the presence of 8 µg/ml polybrene using conditions to achieve >1000× coverage of each shRNA in the library. Infection rate was estimated to be 0.135% and was predicted to achieve predominantly one lentiviral integration per cell. Transduced and nontransduced cells were then treated with 2 µg/ml puromycin. Transduced cells were selected until all cells in the nontransduced plate were dead (2-4 d) to obtain a pure population of transduced cells (MG63.3i).
High-throughput in vivo functional assay. 8-to 10-week-old female SCID/ Beige (Charles River) mice were used for the in vivo study arm. Mice were fed Dox Diet pellets containing 200 mg per kg of pellets doxycycline (Bio-Serve) for 5 d before injection of cells. MG63.3i cells were pretreated with 5 µg/ml doxycycline for 12 h in standard culture before being delivered to mouse lungs through tail vein injection. This primed the cells, but knockdown was not achieved even at the transcript level until 24-72 h after doxycycline addition. 1.5 × 10 6 cells were injected into each mouse (n = 15). Mice were maintained on a Dox diet throughout the 21-d course of the experiment. At the conclusion of the experiment, mice were euthanized through CO 2 inhalation, and lungs were surgically extracted and homogenized using the Tumor Dissociation Kit, human (Miltenyi) according to the manufacturer's protocol. Mouse lung cells were depleted using the Mouse Cell Depletion Kit (Miltenyi) according to the manufacturer's protocol. Lungs from 5 mice were pooled for each replicate to achieve 1,000× engraftment coverage of each shRNA in the library. GFP + dsRed + cells were then isolated through FACS.
Three replicates of 1.5 × 10 6 MG63.3i cells growing in vitro were induced with 5 µg/ml doxycycline and maintained on doxycycline over 21 d in culture. GFP + dsRed + cells were isolated by FACS. Sorted cell counts of in vitro replicates were matched to numbers of cells isolated from the in vivo arm (3 × 10 5 -5 × 10 5 ).
DNA was isolated from three replicates of uninduced MG63.3i cells as well as in vivo and in vitro arms of the experiment.
shRNA amplification and sequencing. Genomic DNA was isolated and sequenced as previously described 60 but with slight modification. Genomic DNA was isolated by two rounds of phenol extraction using 5PRIME Phase Lock tubes (Quantabio) followed by isopropanol precipitation. Deep sequencing libraries were generated through PCR amplification of shRNA guide strands using barcoded primers that tag the product with standard Illumina adapters. For each sample, DNA from at least 3 × 10 5 cells was used as template in multiple parallel 50-µl PCR reactions, each containing 1 µg template, 1× AmpliTaq Gold buffer, 0.2 mM of each dNTP, 0.3 µM of each primer and 2.5 U AmpliTaq Gold (Applied Biosystems), which were run using the following cycling parameters: 95 °C for 10 min; 35 cycles of 95 °C for 30 s, 52 °C for 45 s and 72 °C for 60 s; and 72 °C for 7 min. PCR products (340 nt) were combined for each sample, precipitated, and purified on a 2% agarose gel (QIAquick gel extraction kit, Qiagen). Libraries were sequenced on the HiSeq 2500 platform at the Case Western Reserve University Genomics Core Facility. Libraries were sequenced using a primer that reads in reverse into the guide strand (miR30EcoRISeq, 5′-TAGCCCCTTGAATTCCGAGGCAGTAGGCA-3′). To provide a sufficient baseline for detecting shRNA depletion in experimental samples, we aimed to acquire >1,000 reads per shRNA in all samples, or 1.37 × 10 5 reads per sample. In practice, we achieved >2 × 10 6 reads for all samples. Sequence processing was performed using two custom workflows using https://usegalaxy.org 61 . Workflow can be accessed at the following links: https://usegalaxy.org/u/tyleremiller/w/ shrna-pipeline1 and https://usegalaxy.org/u/tyleremiller/w/shrnastep2. For each shRNA and condition, the number of matching reads was normalized to the total read number per lane. This measure of normalized coverage was used for all downstream analyses.
Inducible knockdown of F3. shRNAs targeting F3 were selected from the transOMIC technologies shERWOOD-UltramiR shRNA library and cloned into the LT3REPIR vector as described in the preceding section. Cloning of shRNA into the backbone construct was performed on contract by transOMIC technolgies.
The shRNA sequences that were tested are listed in Supplementary Table 3 .
Lentiviral production. VSV-G-pseudotyped lentivirus was generated through standard laboratory techniques. Briefly, shRNA-LT3REPIR plasmids were cotransfected with packaging vectors psPAX2 and pCI-VSVG (Addgene) into 293FT cells using Cal-Phos Mammalian Transfection Kit (Clontech). Individual supernatants containing virus were harvested at 48 and 72 h post-transfection and filtered with 0.45 µm PVDF membrane (Millipore).
Lentiviral transduction and selection. Transduction was performed via 24-h exposure to lentivirus in the presence of 8 µg/ml polybrene. Transduced and nontransduced cells were then treated with 2 µg/ml puromycin. Transduced cells were selected until all cells in the nontransduced plate were dead (2-4 d) .
Assessment of knockdown. Optimal shRNA induction was assessed and found to occur with 5 µg/ml doxycycline treatment. MG63.3 cells transduced with shF3A, shF3B, and shF3C were treated with doxycycline for 40 h, trypsinized, and sorted to isolate the GFP + dsRed + fraction. Noninduced cells were sorted to isolate the GFP + fraction. RNA was extracted from 1 × 10 6 cells and purified using the RNAeasy Micro kit (Qiagen) according to the manufacturer's protocol. RNA quality was assessed by 2200 TapeStation Instrument (Agilent). cDNA was synthesized using the High Capacity RNA-to-cDNA kit (ABI) according to the manufacturer's protocol. Knockdown efficiency was determined through RT-qPCR analysis for F3 using optimized TaqMan Gene Expression Assay primers and TaqMan Gene Expression Master Mix (Life Technologies). The probes used for the RT-qPCR are as follows: F3, Hs01076029_m1; GAPDH, Hs02758991_g1.
RT-qPCR was performed to quantify percent knockdown with induction of each hairpin relative to noninduced controls. The shF3A and shF3B hairpins showed the highest degree of F3 knockdown and were chosen for use in the remainder of our studies.
In vivo experimental metastasis model. 8-to 10-week-old female SCID/Beige (Charles River) mice were used for all experimental metastasis studies. For all in vivo experimental F3 knockdown studies, mice in the F3 knockdown group were fed Dox Diet pellets containing 2 mg per kg body weight doxycycline (Bio-Serve) for 5 d before injection of cells. F3 knockdown cells were pretreated with 5 µg/ml doxycycline for 24 h in standard culture. Cells with induced expression of shRNA targetting F3 were sorted through FACS to isolate the GFP + dsRed + fraction. Control cells were sorted to isolate the GFP + fraction.
End-point assessment of lung metastasis. 5 × 10 5 MG63.3 GFP + dsRed + or MG63.3 GFP + cells were injected into the tail vein of each mouse (n = 10 mice per condition). Mice in the F3 knockdown group were maintained on the Dox Diet throughout the experiment. On day 7 or day 14 following injection, 5 mice from each group were euthanized through CO 2 inhalation. Lungs were insufflated with PBS and imaged through inverted fluorescent microscopy (Leica DM IRB) at a magnification of 2.5×. Five images per lung were taken to assess metastatic burden in each mouse.
Image analysis was performed using ImageJ software to quantify the total GFP + area per image. The metastatic burden was calculated as the sum of the total GFP + area in the five images from each mouse.
Survival analysis. 5 × 10 4 cells were injected into the tail vein of each mouse (n = 5 mice per condition). Mice in the F3 knockdown group were maintained on the Dox Diet throughout the experiment. All mice that died underwent complete necropsy examination and confirmation of metastasis.
Orthotopic spontaneous lung metastasis model. 8-to 10-week-old female NSG mice (Jackson) were used for the spontaneous metastasis studies. Mice in the F3 knockdown group were given water supplemented with 2 mg/ml doxycycline hyclate (Sigma) and 2% sucrose for 5 d before injection of cells. F3 knockdown cells were pretreated with 5 µg/ml doxycycline for 24 h in standard culture. F3 shRNA induced cells were sorted through FACS to isolate the GFP + dsRed + fraction. Control cells were sorted to isolate the GFP + fraction. 3 × 10 5 cells were injected orthotopically into the paraosseous region adjacent to the left proximal tibia. For the F3 knockdown group, water was changed and fresh doxycycline was added twice weekly. Injection sites were monitored for tumor formation twice weekly.
Tumors became measureable on day 21 for all groups, at which time tumors were measured in two dimensions twice weekly. Tumor volume was calculated as follows: volume (mm 3 ) = 3.14 × (long dimension (mm)) × (short dimension (mm)) 2 . The experiment was terminated following 21 d of tumor measurements (42 d after injections), and mice were euthanized through CO 2 inhalation. Lungs were insufflated with PBS and imaged through fluorescent microscopy at a magnification of 2.5× using a Leica DM 5500B light microscope with a Leica DFC 500 camera. Five images per lung were taken to assess the metastatic burden in each mouse.
Image analysis was performed using ImageJ software. Micrometastases were defined as GFP + lesions with a diameter >25 pixels in images captured at 2.5× magnification. The number of micrometastases per image was manually counted. The total number of micrometastases for each lung was calculated as the sum of the total number of micrometastases in 5 images from each mouse.
In vitro assay for FXa formation. Cells growing in vitro were pretreated with 25 µg/ml IgG control, monoclonal antibody 10H10, or monoclonal antibody 5G9 20 min before assay. F3 inhibitory antibodies (Mab-10H10 and Mab-5G9) were acquired from the Versteeg laboratory. Validation experiments presented in ref. 37 . Cells were washed in serum-free DMEM, and Xa generation over time was measured 30 min after the addition of 1nM FVIIa and 50 nM FX using the chromogenic substrate Spectrozyme FXa.
Assessment of F3-inhibiting antibodies on metastatic progression. 5 × 10 5 GFP + MG63.3 cells were mixed with 500 µg IgG control, monoclonal antibody 10H10, or monoclonal antibody 5G9 and injected into the tail vein of 10-to 12-week-old female SCID-beige mice (n > 5 mice per group). Mice were euthanized 14 d after injection, and metastatic burden was assessed through whole-lung fluorescent imaging (5 images per mouse). Metastatic burden was quantified as the total GFP + area per mouse.
F3 lung metastasis staining. To assess F3 expression in metastatic tumor cells in lung at progressive time points, mice were injected with 1 × 10 6 cells (via tail vein) and were euthanized via CO 2 inhalation at 24 h and 15 d post-injection. Lungs were harvested, formalin-fixed, and paraffin-embedded. For ex vivo lung metastasis staining, the protocol described above was followed and lung sections were fixed at 24 h and 5 d post-injection. Tissue sections of lungs were cut at a thickness of 5 µm. Prior to immunostaining, paraffin sections were dewaxed with xylenes and rehydrated with an ethanol series. For antigen retrieval, tissue sections were immersed 95 °C Target Retreival Solution (DAKO) for 25 min. Tissue sections were permeabilized with 0.01% Triton-X in PBS for 10 min. Slides were rinsed with PBS and blocked with 4% BSA in PBS for 10 min. The following primary antibodies were used: F3, rabbit monoclonal IgG F3 antibody (ab151748, Abcam); GFP, goat polyclonal IgG GFP antibody conjugated to fluorescein isothiocyanate (FITC; ab6662, Abcam). Primary antibodies were diluted in 4% BSA (1:100), and slides were incubated in antibody solution at 4 °C overnight. Slides were rinsed and incubated with goat polyclonal IgG anti-rabbit IgG (H+L) conjugated to Alexa 594 (A-11037, Life Technologies) diluted 1:200 in 4% BSA for 1 h in a dark humidified slide chamber. Nuclei were visualized with DAPI (Sigma, 1 µg/ml). Tissue sections were mounted on slides using anti-fade mounting medium (Vectashield).
Stained sections were imaged by fluorescent microscopy at 20× or 40× using a Leica DM 5500B light microscope with a Leica DFC 500 camera. Image analysis was performed using ImageJ software. F3 expression was computed within the GFP + metastatic tumor cell area.
Tissue array staining and scoring. A tissue microarray that we previously developed containing 20 lung metastases from individuals with osteosarcoma 62 was assessed for F3 expression. 18 of these 20 samples had cores of sufficient quality on the stained slide to be scored. For staining, paraffin was removed through a 5 min incubation in a xylene bath performed twice and then rehydrated using step-down concentrations of ethanol. Antigen retrieval was performed through incubation in 1:10 dilution of Target Retrieval Solution (DAKO) in a steamer for 25 min at 95 °C. Cells were permeabilized with 0.01% Triton-X in PBS for 10 min. F3 immunohistochemical staining was performed using rabbit monoclonal IgG F3 antibody (ab151748, Abcam) and the EnVision + System-HRP (Dako) according to the manufacturer's protocol. Cover slips were mounted on slides using anti-fade mounting medium.
The array was scored by the Director of Soft Tissue Pathology at the Cleveland Clinic and Learner Research Institute who was blinded to the sample type. Cores were scored based on the percentage of tumor cells in the core with positive staining for F3 (0 = 0%; 1+ = 1-25%; 2+ = 26-50%; 3+ = >50%) and the intensity of F3 staining in positive areas (low-intensity staining or high-intensity staining). Individual cores were excluded from the analysis if no tumor was present, if the tumor was predominantly necrotic, or if the core was falling off the slide.
Targeted deletion of an F3 Met-VEL by genome engineering. Two TALEN dimers were designed to target the flanks of the Met-VEL in the F3 locus, as indicated in Figure 5a . TALEN dimers recognized the sequences 5′-ACCAAC TCACTTGAGCTGtgtggtttttcttCAGTGCACAATTGTGAAAT-3′ and 5′-GA ATCGACTGATCAAAGCacatgaactttttaaaaaaGAGTAATAAGTTTACTT-3′, where spacer elements are in lower case. TALEN constructs were assembled with adaptations of previously described protocols 63, 64 . MG63.3 cells were grown in a 6-well plate format to 70% confluence and transfected with 2.5 µg plasmid for each TALEN monomer using Lipofectamine 2000 (ThermoFisher Scientific) per the manufacturer's instructions. Cells were incubated for 48 h at 30 °C, and genomic DNA was subsequently harvested using QuickExtract DNA Extraction Solution (Epicentre) as recommended by the supplier. Efficient deletion of the F3 Met-VEL was confirmed through agarose gel electrophoresis of PCR products generated using the primers 5′-GCAGTGCACAACCTGTACAAC-3′ and 5′-TTGGCCAGGGTCATTATGTT-3′ (Integrated DNA Technologies) and high-fidelity AccuPrime Taq DNA Polymerase (ThermoFisher Scientific). Single-cell clones were derived through limiting dilution, and genotypes were confirmed as described above. Enhancer deletion of the clonal cell population used for functional metastasis experiments was confirmed through Sanger sequencing using the primer sequences listed above.
Life Sciences Reporting Summary. Further information on experimental design is available in the Life Sciences Reporting Summary.
Data availability. The datasets generated during and analyzed during the current study are included within the published manuscript (and supplementary information) or have been deposited in Gene Expression Omnibus (RNA-seq, ChIP-seq, DNase-seq data) under accession number GSE74230. All other data are available from the corresponding authors upon reasonable request.
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